Skip to Content

Outlier Patients in Cancer Drug Trials Could Personalize Treatment

Researchers use DNA sequencing to identify the molecular basis of a patient’s unique but beneficial response to an experimental cancer drug.

No cancer is like any other, so it’s no surprise that there’s a lot of variability in how patients respond to cancer drugs. This variability creates a challenge for drug developers: A  compound can fail in clinical trials if it does not reverse or at least stall disease progression in a significant percentage of patients, even if it greatly helps some.

Researchers at Memorial Sloan-Kettering Cancer Center in New York examined one such case in a clinical trial of a drug called everolimus. While most patients in the trial were not helped by the drug, one did experience a remarkable recovery. The metastatic bladder cancer of this patient disappeared after a few months on everolimus.

By comparing the genome of this patient’s cancer to his or her healthy genome, the researchers identified a mutation in a gene known to be linked to everolimus’ molecular target. They then looked for mutations in the same gene in 13 other patients involved in the trial. Of the four additional patients with mutations in that gene, three had shown minor positive responses to everolimus, the team reports today in Science.

The authors write that the results show that tumor genome sequencing can identify previously unrecognized biomarkers for drug response in solid tumors. They also suggest that the genomes of tumors from “outlier” patients, who respond to a drug when many others don’t, may provide clues for identifying other patients who could also be helped by the treatment

“Although single patient anecdotes are often dismissed as failing to provide meaningful clinical evidence, this example illustrates the potential for such cases to inform future clinical development of drugs in molecularly defined populations.”

Keep Reading

Most Popular

Death and Jeff Bezos
Death and Jeff Bezos

Meet Altos Labs, Silicon Valley’s latest wild bet on living forever

Funders of a deep-pocketed new "rejuvenation" startup are said to include Jeff Bezos and Yuri Milner.

tonga eruption
tonga eruption

Tonga’s volcano blast cut it off from the world. Here’s what it will take to get it reconnected.

The world is anxiously awaiting news from the island—but on top of the physical destruction, the eruption has disconnected it from the internet.

mouse engineered to grow human hair
mouse engineered to grow human hair

Going bald? Lab-grown hair cells could be on the way

These biotech companies are reprogramming cells to treat baldness, but it’s still early days.

conceptual illustration showing various women's faces being scanned
conceptual illustration showing various women's faces being scanned

A horrifying new AI app swaps women into porn videos with a click

Deepfake researchers have long feared the day this would arrive.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.